TW202227643A - 對於免疫檢查點抑制劑之反應的預測方法 - Google Patents

對於免疫檢查點抑制劑之反應的預測方法 Download PDF

Info

Publication number
TW202227643A
TW202227643A TW110134919A TW110134919A TW202227643A TW 202227643 A TW202227643 A TW 202227643A TW 110134919 A TW110134919 A TW 110134919A TW 110134919 A TW110134919 A TW 110134919A TW 202227643 A TW202227643 A TW 202227643A
Authority
TW
Taiwan
Prior art keywords
subject
group
immune checkpoint
set threshold
acid
Prior art date
Application number
TW110134919A
Other languages
English (en)
Chinese (zh)
Inventor
砂川優
的場亮
Original Assignee
日商小野藥品工業股份有限公司
特定非營利活動法人日本癌臨床試驗推進機構
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商小野藥品工業股份有限公司, 特定非營利活動法人日本癌臨床試驗推進機構 filed Critical 日商小野藥品工業股份有限公司
Publication of TW202227643A publication Critical patent/TW202227643A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
TW110134919A 2020-09-18 2021-09-17 對於免疫檢查點抑制劑之反應的預測方法 TW202227643A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-157940 2020-09-18
JP2020157940 2020-09-18

Publications (1)

Publication Number Publication Date
TW202227643A true TW202227643A (zh) 2022-07-16

Family

ID=80776174

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110134919A TW202227643A (zh) 2020-09-18 2021-09-17 對於免疫檢查點抑制劑之反應的預測方法

Country Status (3)

Country Link
JP (1) JPWO2022059785A1 (https=)
TW (1) TW202227643A (https=)
WO (1) WO2022059785A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025048570A1 (ko) * 2023-08-31 2025-03-06 의료법인 성광의료재단 신장암에서 면역 관문 억제제의 치료 반응성 예측 마커 및 이를 이용한 치료 반응성 예측 방법
EP4617665A1 (en) * 2024-03-14 2025-09-17 Centre National de la Recherche Scientifique An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large b-cell lymphoma
WO2025191110A1 (en) * 2024-03-14 2025-09-18 Centre National De La Recherche Scientifique An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large b-cell lymphoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377693B2 (en) * 2014-12-09 2022-07-05 Merck Sharp & Dohme Llc System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
WO2016175275A1 (ja) * 2015-04-30 2016-11-03 国立大学法人京都大学 Ｐｄ－ｌ１（ｃｄ２７４）の異常を指標としたｐｄ－１／ｐｄ－ｌ１阻害剤の治療効果予測方法
KR102708641B1 (ko) * 2016-09-27 2024-09-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
EP3773915A2 (en) * 2018-03-28 2021-02-17 Seres Therapeutics, Inc. Treatment of a cancer by microbiome modulation
EP3804758A4 (en) * 2018-05-31 2022-03-02 ONO Pharmaceutical Co., Ltd. BIOMARKERS TO EVALUATE THE EFFECTIVENESS OF AN IMMUNE CHECKPOINT INHIBITOR
US12551515B2 (en) * 2018-11-21 2026-02-17 Board Of Regents Of The University Of Texas System Methods and compositions for treating cancer

Also Published As

Publication number Publication date
JPWO2022059785A1 (https=) 2022-03-24
WO2022059785A1 (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
Huang et al. Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression
Qu et al. A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population
Song et al. Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody
Otandault et al. Recent advances in circulating nucleic acids in oncology
Shields et al. Indicators of responsiveness to immune checkpoint inhibitors
Xiong et al. Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer
Scherr et al. Differential expression of miR-17∼ 92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia
Kadara et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis
CN108138236A (zh) 用于癌症中免疫治疗的基因标签
Ryzhakov et al. Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation
Chen et al. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1
TW202227643A (zh) 對於免疫檢查點抑制劑之反應的預測方法
JP2025026905A (ja) ヒト腫瘍のがん細胞における分子活性を定量化するための方法
Pitter et al. PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages
WO2023284789A1 (zh) 人食管鳞状细胞癌的分子标记物组及其应用
Ji et al. Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups
Bai et al. Shaping immune landscape of colorectal cancer by cholesterol metabolites
Duttagupta et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
Aigelsreiter et al. Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma
Kovalski et al. Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity
Zhuang et al. Proteomic characteristics reveal the signatures and the risks of T1 colorectal cancer metastasis to lymph nodes
Morad et al. Microbial signals in primary and metastatic brain tumors
Wu et al. A Risk Model Based on Ferroptosis‐Related Genes OSMR, G0S2, IGFBP6, IGHG2, and FMOD Predicts Prognosis in Glioblastoma Multiforme
US20230235406A1 (en) Immunoglobulin expression levels as biomarker for proteasome inhibitor response
Lu et al. Multi-omics profiling reveals downregulated tumor lysine metabolism reshaping the immune microenvironment and therapeutic responses in hepatocellular carcinoma